Excess Serum Interleukin-18 Distinguishes Patients With Pathogenic Mutations in PSTPIP1.
Acne Vulgaris
/ blood
Adaptor Proteins, Signal Transducing
/ genetics
Adolescent
Adult
Arthritis, Infectious
/ blood
Child
Child, Preschool
Cytoskeletal Proteins
/ genetics
Female
Humans
Infant
Interleukin-18
/ blood
Male
Middle Aged
Mutation
Pyoderma Gangrenosum
/ blood
Retrospective Studies
Young Adult
Journal
Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
04
08
2021
received:
02
02
2021
accepted:
02
09
2021
pubmed:
8
9
2021
medline:
19
2
2022
entrez:
7
9
2021
Statut:
ppublish
Résumé
Dominantly inherited PSTPIP1 mutations cause a spectrum of autoinflammatory manifestations epitomized by PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome.). The connections between PSTPIP1 and PAPA syndrome are poorly understood, although evidence suggests involvement of pyrin inflammasome activation. Interleukin-18 (IL-18) is an inflammasome-activated cytokine associated with susceptibility to macrophage activation syndrome (MAS). This study was undertaken to investigate an association of IL-18 with PAPA syndrome. Clinical and genetic data and serum samples were obtained from patients referred to institutions due to symptoms indicative of PAPA syndrome. Serum IL-18, IL-18 binding protein (IL-18BP), and CXCL9 levels were assessed by bead-based assay, and free IL-18 levels were assessed by enzyme-linked immunosorbent assay. The symptoms of PSTPIP1-positive patients with PAPA syndrome overlapped with those of mutation-negative patients with PAPA-like conditions, but mutation-positive patients had earlier onset and a greater proportion had a history of arthritis. We found uniform elevation of total serum IL-18 in treated PAPA syndrome patients at levels nearly as high as those seen in NLRC4-associated autoinflammation with infantile enterocolitis patients, and well above levels found in most familial Mediterranean fever patients. Serum IL-18 elevation in PAPA syndrome patients persisted despite fluctuations in disease activity. Levels of the soluble IL-18 antagonist IL-18BP were modestly elevated, and PAPA syndrome patients had detectable free IL-18. PAPA syndrome was rarely associated with elevation of CXCL9, an indicator of interferon-γ activity, but no PAPA syndrome patients had a history of MAS. PAPA syndrome is a refractory and often disabling monogenic autoinflammatory disease associated with chronic and unopposed elevation of serum IL-18 levels but not with risk of MAS. These findings affect our understanding of the diseases in which IL-18 is overproduced and suggest a link between pyrin inflammasome activation, IL-18, and autoinflammation, without susceptibility to MAS.
Identifiants
pubmed: 34492165
doi: 10.1002/art.41976
pmc: PMC8855702
mid: NIHMS1738472
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Cytoskeletal Proteins
0
IL18 protein, human
0
Interleukin-18
0
PSTPIP1 protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
353-357Subventions
Organisme : NICHD NIH HHS
ID : R01 HD098428
Pays : United States
Organisme : the RK Mellon Institute for Pediatric Research
Organisme : the National Institute of Allergy and Infectious Disease
Organisme : National Institute of Allergy and Infectious Disease, NIH
Organisme : Intramural Research Programs of the National Human Genome Research Institute
Organisme : Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH
Organisme : the Institut d'Investigacions Biomediques August Pi i Sunyer
Organisme : the University Hospital of Geneva
Informations de copyright
© 2021, American College of Rheumatology.
Références
Blood. 2020 Nov 5;136(19):2162-2174
pubmed: 32589707
Immunol Rev. 2018 Jan;281(1):138-153
pubmed: 29247988
Arthritis Rheum. 2010 Aug;62(8):2556-8
pubmed: 20506269
Rheumatology (Oxford). 2016 Dec;55(12):2237-2247
pubmed: 27616144
J Exp Med. 2019 Dec 2;216(12):2778-2799
pubmed: 31601675
J Allergy Clin Immunol. 2019 Oct;144(4):1122-1125.e6
pubmed: 31271789
J Exp Med. 2017 Jan;214(1):59-71
pubmed: 27994071
J Allergy Clin Immunol. 2021 Jul;148(1):250-255.e1
pubmed: 33338535
Hum Mol Genet. 2002 Apr 15;11(8):961-9
pubmed: 11971877
Blood. 2018 Mar 29;131(13):1442-1455
pubmed: 29326099
J Allergy Clin Immunol. 2015 Nov;136(5):1337-45
pubmed: 26025129
Mol Cell. 2007 Oct 26;28(2):214-27
pubmed: 17964261
Cell Biol Int. 2015 Dec;39(12):1384-94
pubmed: 26179737
Front Immunol. 2020 Jun 11;11:716
pubmed: 32655537
Arthritis Rheum. 2012 Jun;64(6):2022-7
pubmed: 22161697
Curr Opin Rheumatol. 2016 Sep;28(5):550-9
pubmed: 27464597